| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abstracts
|
|
|
2003
|
82 |
1 |
p. 1-184
|
artikel
|
| 2 |
Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™)
|
Ilka B. Fuchs
|
|
2003
|
82 |
1 |
p. 23-28
6 p.
|
artikel
|
| 3 |
Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™)
|
Fuchs, Ilka B.
|
|
2003
|
82 |
1 |
p. 23-28
|
artikel
|
| 4 |
E2F1 Expression is Related with the Poor Survival of Lymph Node-positive Breast Cancer Patients Treated with Fluorouracil, Doxorubicin and Cyclophosphamide
|
Sehwan Han
|
|
2003
|
82 |
1 |
p. 11-16
6 p.
|
artikel
|
| 5 |
E2F1 Expression is Related with the Poor Survival of Lymph Node-positive Breast Cancer Patients Treated with Fluorouracil, Doxorubicin and Cyclophosphamide
|
Han, Sehwan
|
|
2003
|
82 |
1 |
p. 11-16
|
artikel
|
| 6 |
Familial Breast Cancer: Scope for More Susceptibility Genes
|
Kari Hemminki
|
|
2003
|
82 |
1 |
p. 17-22
6 p.
|
artikel
|
| 7 |
Familial Breast Cancer: Scope for More Susceptibility Genes?
|
Hemminki, Kari
|
|
2003
|
82 |
1 |
p. 17-22
|
artikel
|
| 8 |
Index
|
|
|
2003
|
82 |
1 |
p. 185-195
|
artikel
|
| 9 |
Instructions for Authors
|
|
|
2003
|
82 |
1 |
p. 71-74
4 p.
|
artikel
|
| 10 |
Instructions for Authors
|
|
|
2003
|
82 |
1 |
p. 71-74
|
artikel
|
| 11 |
Keeping Data Continuous when Analyzing the Prognostic Impact of a Tumor Marker: An Example with Cathepsin D in Breast Cancer
|
N. Bossard
|
|
2003
|
82 |
1 |
p. 47-59
13 p.
|
artikel
|
| 12 |
Keeping Data Continuous when Analyzing the Prognostic Impact of a Tumor Marker: An Example with Cathepsin D in Breast Cancer
|
Bossard, N.
|
|
2003
|
82 |
1 |
p. 47-59
|
artikel
|
| 13 |
Perioperative Screening for Metastatic Disease is not Indicated in Patients with Primary Breast Cancer and no Clinical Signs of Tumor Spread
|
Bernd Gerber
|
|
2003
|
82 |
1 |
p. 29-37
9 p.
|
artikel
|
| 14 |
Perioperative Screening for Metastatic Disease is not Indicated in Patients with Primary Breast Cancer and no Clinical Signs of Tumor Spread
|
Gerber, Bernd
|
|
2003
|
82 |
1 |
p. 29-37
|
artikel
|
| 15 |
Phase I Trial of UracilFtorafur, Leucovorin, and Etoposide: An Active All-oral Regimen for Metastatic Breast Cancer
|
Anne-Renee Hartman
|
|
2003
|
82 |
1 |
p. 61-69
9 p.
|
artikel
|
| 16 |
Phase I Trial of Uracil–Ftorafur, Leucovorin, and Etoposide: An Active All-oral Regimen for Metastatic Breast Cancer
|
Hartman, Anne-Renee
|
|
2003
|
82 |
1 |
p. 61-69
|
artikel
|
| 17 |
p53 Inactivation is a Rare Event in Familial Breast Tumors Negative for BRCA1 and BRCA2 Mutations
|
Elisa Sensi
|
|
2003
|
82 |
1 |
p. 1-9
9 p.
|
artikel
|
| 18 |
p53 Inactivation is a Rare Event in Familial Breast Tumors Negative for BRCA1 and BRCA2 Mutations
|
Sensi, Elisa
|
|
2003
|
82 |
1 |
p. 1-9
|
artikel
|
| 19 |
Predictive Factors for the Status of Non-sentinel Nodes in Breast Cancer Patients with Tumor Positive Sentinel Nodes
|
Vincent van Iterson
|
|
2003
|
82 |
1 |
p. 39-45
7 p.
|
artikel
|
| 20 |
Predictive Factors for the Status of Non-sentinel Nodes in Breast Cancer Patients with Tumor Positive Sentinel Nodes
|
van Iterson, Vincent
|
|
2003
|
82 |
1 |
p. 39-45
|
artikel
|
| 21 |
26th Annual San Antonio Breast Cancer Symposium, Program Schedule
|
|
|
2003
|
82 |
1 |
p. v-xxx
|
artikel
|
Tijdschrift beschrijving